biostudies-literatureUnknown262(2)Sotani-Ogawa RKobe University<h4>Purpose</h4>This pilot study aims to comprehensively evaluate the effects of sub-Tenon's injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).<h4>Methods</h4>This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70-180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.<h4>Results</h4>The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (P = 0.625 for TIR, P = 0.250 for TAR, and P = 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.<h4>Conclusion</h4>Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie449-456https://www.ebi.ac.uk/biostudies/studies/S-EPMC10844153biostudies-literatureContinuous glucose monitoring metrics following sub-Tenon's injection of triamcinolone acetonide for diabetic macular edema.PMC10844153Nakamura MOgawa WKusuhara SKim KWHirota YSotani-Ogawa RMatsumiya WfalseContinuous glucose monitoring metrics following sub-Tenon's injection of triamcinolone acetonide for diabetic macular edema.<h4>Purpose</h4>This pilot study aims to comprehensively evaluate the effects of sub-Tenon's injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).<h4>Methods</h4>This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70-180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.<h4>Results</h4>The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (P = 0.625 for TIR, P = 0.250 for TAR, and P = 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.<h4>Conclusion</h4>Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.2024-01-01T00:00:00Z2024 Feb2025-04-26T03:27:28.996Z2025-04-06T10:45:58.04ZS-EPMC108441533786463610.1007/s00417-023-06275-y